These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7831364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ginkgolide BN 52021 protects against hemorrhagic shock-induced renal injury in rats.
    Kirejczyk JK, Chyczewski L, Debek W.
    Rocz Akad Med Bialymst; 1995; 40(1):65-76. PubMed ID: 8528996
    [Abstract] [Full Text] [Related]

  • 3. [Platelet-activating factor (PAF) antagonists].
    Terasawa M.
    Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
    [No Abstract] [Full Text] [Related]

  • 4. Oxygen-derived free radicals in kidney in experimental hemorrhagic shock treated by PAF-receptor antagonist BN 52021.
    Kirejczyk JK, Debek W, Dziecioł J, Chyczewski L, Makarewicz M, Nikliński J.
    Rocz Akad Med Bialymst; 1995 Feb; 40(1):77-87. PubMed ID: 8528997
    [Abstract] [Full Text] [Related]

  • 5. Effect of PAF-antagonists in endotoxin shock--ovine and rat experiments.
    Bahrami S, Redl H, Thurnher M, Vogl C, Paul E, Schiesser A, Schlag G.
    Prog Clin Biol Res; 1989 Feb; 308():931-6. PubMed ID: 2780740
    [No Abstract] [Full Text] [Related]

  • 6. Role of platelet-activating factor in hepatocellular Ca2+ alterations during hemorrhagic shock.
    Silomon M, Pizanis A, Larsen R, Rose S.
    J Surg Res; 1997 Oct; 72(2):101-6. PubMed ID: 9356229
    [Abstract] [Full Text] [Related]

  • 7. Role of PAF and cytokines in microvascular tissue injury.
    Koltai M, Hosford D, Braquet P.
    J Lab Clin Med; 1992 May; 119(5):461-6. PubMed ID: 1316420
    [No Abstract] [Full Text] [Related]

  • 8. Ginkgolides and platelet-activating factor binding sites.
    Hosford DJ, Domingo MT, Chabrier PE, Braquet P.
    Methods Enzymol; 1990 May; 187():433-46. PubMed ID: 2172741
    [No Abstract] [Full Text] [Related]

  • 9. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.
    Fletcher JR, DiSimone AG, Earnest MA.
    Ann Surg; 1990 Mar; 211(3):312-6. PubMed ID: 2178565
    [Abstract] [Full Text] [Related]

  • 10. Platelet-activating factor antagonists: scientific background and possible clinical applications.
    Koltai M, Guinot P, Hosford D, Braquet PG.
    Adv Pharmacol; 1994 Mar; 28():81-167. PubMed ID: 8080821
    [No Abstract] [Full Text] [Related]

  • 11. Recent progress in ginkgolide research.
    Braquet P, Esanu A, Buisine E, Hosford D, Broquet C, Koltai M.
    Med Res Rev; 1991 May; 11(3):295-355. PubMed ID: 1647474
    [No Abstract] [Full Text] [Related]

  • 12. Luminol-chemiluminescence in free peritoneal cells in hemorrhagic shock in rats treated with PAF-receptor-antagonist BN 52021.
    Debek W, Gruca P, Chyczewski L, Gruca A.
    Rocz Akad Med Bialymst; 1995 May; 40(1):129-37. PubMed ID: 8528982
    [Abstract] [Full Text] [Related]

  • 13. Modulation of long-term potentiation in the CA1 area of rat hippocampus by platelet-activating factor.
    Kato K.
    Adv Exp Med Biol; 1999 May; 469():221-7. PubMed ID: 10667334
    [No Abstract] [Full Text] [Related]

  • 14. PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists.
    Koltai M, Hosford D, Braquet P.
    J Lipid Mediat; 1993 May; 6(1-3):183-98. PubMed ID: 8357981
    [No Abstract] [Full Text] [Related]

  • 15. A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia.
    Moore JM, Earnest MA, DiSimone AG, Abumrad NN, Fletcher JR.
    Circ Shock; 1991 Sep; 35(1):53-9. PubMed ID: 1660355
    [Abstract] [Full Text] [Related]

  • 16. PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists.
    Dive G, Godfroid JJ, Lamotte-Brasseur J, Batt JP, Heymans F, Dupont L, Braquet P.
    J Lipid Mediat; 1989 Sep; 1(4):201-15. PubMed ID: 2562434
    [Abstract] [Full Text] [Related]

  • 17. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP.
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [Abstract] [Full Text] [Related]

  • 18. [The role of the thrombocyte-activating factor in the development of circulatory disorders in the postischemic shock reaction].
    Sagach VF, Dmitrieva AV.
    Fiziol Zh (1978); 1990 Nov; 36(4):8-14. PubMed ID: 2172032
    [Abstract] [Full Text] [Related]

  • 19. Synergetic protective effects of combined blockade by two kinds of autolesion mediator receptor on neurological function after cervical cord injury.
    Xiao J, Zhao D, Hou T, Wu K, Zeng H.
    Chin Med J (Engl); 1998 May; 111(5):443-6. PubMed ID: 10374355
    [Abstract] [Full Text] [Related]

  • 20. Influence of inhibitors of the eicosanoid metabolism, and of eicosanoids- and PAF-acether antagonists on mortality and some biochemical parameters of three shock models.
    Bahr T, Schaper U, Becker K, Lueddeckens G, Förster W, Scheuch DW, Grupe R.
    Prog Clin Biol Res; 1989 May; 301():229-33. PubMed ID: 2798447
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.